Results 81 to 90 of about 22,494 (197)
c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration [PDF]
, 2009 Cytoskeleton dynamics are regulated by Src-family tyrosine kinases (SFKs) and c-Abl. We found that the SFK members Hck and c-Fgr regulate tyrosine phosphorylation of c-Abl and c-Abl associates with β1 integrin-bound Hck or c-Fgr in murine macrophages ...
B George +6 more
core +1 more source
Journal of Cosmetic Dermatology, Volume 24, Issue 9, September 2025.ABSTRACT Background Patients treated with cancer therapies often experience changes in physical appearance, body image perception, and self‐esteem, which influence their quality of life (QoL). Aims To assess the effect of treatment with hyaluronic acid (HA) dermal fillers on QoL, safety, and perceived skin changes of oncology patients. Methods A single‐
Eden Bar +8 more
wiley +1 more source
The teratogenic effects of imatinib mesylate on rat fetuses
Toxicology Reports, 2015 Imatinib mesylate, a selective tyrosine kinase inhibitor, is the first line treatment against chronic myelogenous leukemia and gastrointestinal stromal tumors.
M.M. El Gendy +3 more
doaj +1 more source
Advances in Hematology, 2010 Imatinib mesylate, showed encouraging activity in chronic myelogenous leukemia. However, there are few data regarding his efficacy and response monitoring in Sub-Saharan African patients. Our objective was to assess response to imatinib mesylate (Glivec)
K. G. Koffi +13 more
doaj +1 more source
Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
Turkish Journal of Hematology, 2016 INTRODUCTION: The aim of this study was to investigate the effects of imatinib mesylate on platelet aggregation and adenosine triphosphate (ATP) release in chronic myeloid leukemia patients. METHODS: Platelet aggregation and ATP release induced by 5.0 mM
Olga Meltem Akay +2 more
doaj +1 more source
Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy [PDF]
, 2009 Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the alimentary tract and are believed to derive from the interstitial Cell of Cajal.
Shohrat Annaberdyev +2 more
core +1 more source
The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]
, 2017 Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core +1 more source
Serious Skin Reaction Associated with Imatinib in a Patient with Chronic Myeloid Leukemia
Eurasian Journal of Medicine, 2011 Imatinib mesylate (STI 571) is one of the fundamental chemotherapeutic agents used in the treatment of the chronic, accelerated and blastic phases of chronic myelocytic leukemia (CML), gastrointestinal stromal tumors and Philadelphia chromosome–positive ...
Murat Albayrak +6 more
doaj
Case Reports in Oncological Medicine, 2011 Imatinib mesylate is a tyrosine kinase inhibitor of c-KIT and PDGFRA. Imatinib mesylate is an effective drug that can be used as a first-choice agent for treatment of GISTs. Prior to treatment, molecular diagnosis of c-KIT or PDGFRA is necessary; however,
Kazunori Otsuka +10 more
doaj +1 more source
Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment [PDF]
, 2018 Background: Imatinib mesylate blocks the tyrosine kinase activity of KIT (CD117) and is an effective treatment for gastrointestinal stromal tumors. In multiple myeloma, KIT expression has been detected by flow cytometry in about 33% of specimens, but no ...
Dirnhofer, S. +4 more
core